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Available online 4 May 2020Since the declaration of the coronavirus disease 2019
(COVID-19) pandemic status, the total number of cases
developing severe acute respiratory syndrome coronavirus-
2 (SARS-CoV-2) infection has reached 1,696,588 worldwide,
with a mortality rate of 6.24%.1 Interestingly, reports have
shown that, compared to adults, the pediatric populations
have lower infection rates, less severe clinical presentation
with lower likelihood of progression, and more favorable
prognosis.2 However, the mechanism behind this phenom-
enon remains elusive. Recently, we demonstrated that
COVID-19 severity in adult patients was strongly associated
with higher interleukin-6 (IL-6) levels.3 Thus, in this article,
we aimed to evaluate the current evidence regarding IL-6
levels in pediatric COVID-19 cases.
Records, dated up to April 5th, 2020, were identified
through electronic databases with search terms such as
“COVID-19,” “SARS-CoV-2,” “IL-6,” “pediatrics,” “neo-
nates,” “infants,” “children,” and “adolescents.” No lan-
guage restrictions were applied. We synthesized the data
from seven studies with a total sample size of n Z 127
pediatric patients, with ages ranging from newborn to
adolescence.4e10 Subsequently, one study was excluded10* Corresponding author.
E-mail address: zulhaq@kedokteran.uin-malang.ac.id (Z.S.
Ulhaq).
1 These authors share first co-authorship to this manuscript.
https://doi.org/10.1016/j.pedneo.2020.04.007
1875-9572/Copyrightª 2020, Taiwan Pediatric Association. Published by
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).due to samples testing negative for SARS-CoV-2 The final
sample yielded a size of n Z 117, with slightly higher
infection rates among males (59.8%), which is consistent
with previous reports.5
In contrast to our previous result in adults,3 we observed
that pediatric COVID-19 cases had IL-6 levels within normal
range (mean: 86.3%; range from 67 to 100%) (Table 1) and
that all of the current studies observed patients having mild
symptoms. To illustrate, a study with a representative
population range of three days to 16 years of age5 found an
overall mild clinical presentation among cases and
increased IL-6 levels were only observed in 17.14% of the
total population. In line with this finding, the tendency of
mild clinical presentation in children has likewise been
recognized in a large epidemiologic study of 2163 children
in China11, among which only 0.6% progressed into severe
disease.
This finding reinforces previous notions that the cytokine
storm, indicated by excessive circulating IL-6, is a possible
mechanism of COVID-19 progression3 and that this aggres-
sive inflammatory cascade is less likely to occur in children.
The findings also emphasize that IL-6 better reflects the
severity of COVID-19 clinical presentation and is relatively
more consistent compared to other inflammatory markers
such as C-reactive protein (CRP).12
Several factors may contribute to the milder presenta-
tion observed in children in regard to the immunopatho-
genic response. The less mature immune system of childrenElsevier Taiwan LLC. This is an open access article under the CC BY-
Table 1 Characteristic of included studies.
Characteristics Zhang et al.4 Yu et al.5 Du et al.6 Sun et al.7 Su et al.8 Zeng et al.9
Location China China China China China China
Number of cases 3 82 14 8 9 1
Age 6e9 years 3 days - 16 years 6.20 (median) 2 mo - 15 years 11 mo - 9 years 2 weeks (neonates)
Males, % 100 62.2 42.9 75 33.3 100
Major clinical
feature
Mild Mild Mild-intermediate Mild Asymptomatic - mild Mild
IL-6 67% 4 82.86% 4 92.85% 4 75% 4 100% 4 4
4 value within the normal reference range.
254 G.V. Soraya, Z.S. Ulhaqmay result in the lower capability to elicit cytokine release
against viral infection, relative to the more mature and
vigorous immune responses observed in adults. Other
possible explanations include healthier respiratory tracts
and less pre-existing damage in children compared to
adults.
There are several limitations identified in this current
analysis. Only a few studies reported the IL-6 level in
COVID-19-infected pediatric patient, with some variations
on the IL-6 reference ranges between studies. Thus, further
studies with larger sample size and homogenous or stan-
dardized measurement are needed to confirm these find-
ings. Additionally, more studies need to focus on the
neonate age group, as data regarding clinical presentation
of COVID-19 in this highly susceptible age group remains
scant. In summary, these findings confirm that IL-6 reflect
presence of marked inflammation and severe COVID-19.
Based on current evidence, IL-6 levels of children with
SARS-CoV-2 infection tend to be within normal range, which
reflects the mild nature of clinical presentation in the pe-
diatric population.
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